Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Poly(ADP-ribose) Polymerase Inhibitors 42%
3. Neoplasms 37%
4. veliparib 31%
5. Platinum 29%
6. Ovarian Epithelial Carcinoma 25%
7. gemcitabine 24%
8. Paclitaxel 22%
9. niraparib 20%
10. Drug Therapy 19%
11. Survival 17%
12. tanespimycin 15%
13. olaparib 15%
14. Heterografts 14%
15. Therapeutics 14%
16. Carboplatin 14%
17. pembrolizumab 14%
18. Letrozole 13%
19. Progression-Free Survival 13%
20. Carcinoma 13%
21. Somatomedin Receptors 13%
22. Triple Negative Breast Neoplasms 12%
23. rucaparib 11%
24. Endometrial Neoplasms 11%
25. Homologous Recombination 11%
26. Topotecan 10%
27. (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 10%
28. BMS 536924 10%
29. OSI 027 10%
30. Mechanistic Target of Rapamycin Complex 2 10%
31. Group III Phospholipases A2 10%
32. AMG 479 10%
33. Mutation 10%
34. epacadostat 10%
35. Clinical Trials 9%
36. Estrogen Receptors 9%
37. MDX-H210 antibody 9%
38. Nicotinamide N-Methyltransferase 8%
39. protein kinase C lambda 8%
40. ribociclib 8%
41. Fallopian Tubes 8%
42. Ovary 8%
43. cediranib 8%
44. navitoclax 8%
45. Apoptosis 8%
46. Folate Receptor 1 8%
47. Puma 7%
48. Auranofin 7%
49. TOR Serine-Threonine Kinases 7%
50. Emergencies 7%